CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.59 -0.41 (-0.76%)

Delayed Quote Updated: 10:32 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

37 38 Next >

3 Top Healthcare Stocks Defying the Bear Market ↗

September 15, 2023

Revenue at all three companies improved last quarter, and their share prices have followed suit.

Via The Motley Fool

Better Bull Market Buy: CRISPR vs. Medtronic Stock ↗

September 14, 2023

Investors may look for growth stocks ahead of the next bull market.

Via The Motley Fool

3 Biotech Blockbusters to Turn $5,000 Into $50,000 ↗

September 12, 2023

These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.

Via InvestorPlace

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics ↗

September 12, 2023

These companies are innovators, something that can prove highly lucrative.

Via The Motley Fool

2 No-Brainer Biotech Stocks to Buy Right Now ↗

September 12, 2023

You can get in early on these potential winners.

Via The Motley Fool

CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down ↗

September 07, 2023

With CRISPR Therapeutics announcing the departure of its co-founder, investors are also walking for the exits on CRSP stock.

Via InvestorPlace

What 13 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

August 14, 2023

Via Benzinga

2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street ↗

September 06, 2023

Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.

Via The Motley Fool

With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock? ↗

September 05, 2023

Big news could come in December and in March.

Via The Motley Fool

The 3 Best Biotech Stocks to Buy Now: September 2023 ↗

September 04, 2023

With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.

Via InvestorPlace

2 Spectacular Growth Stocks You Can Buy in September With No Hesitation ↗

September 03, 2023

There's no need for any anxiety with investing in these great stocks.

Via The Motley Fool

3 Beaten-Down Biotech Stocks Bound for a Bounce Back ↗

September 02, 2023

Biotech stocks are still below their post-pandemic peaks. But these beaten-down biotech stocks could lead the sector to new highs.

Via InvestorPlace

Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again ↗

August 30, 2023

The famous growth investor has been making some interesting stock moves lately.

Via The Motley Fool

3 Surprisingly Underrated Stocks to Buy Right Now ↗

August 26, 2023

These stocks deserve more respect than they're getting.

Via The Motley Fool

Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge ↗

August 24, 2023

Via Benzinga

Topics Artificial Intelligence

Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks ↗

August 24, 2023

The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases.

Via The Motley Fool

3 Clever Tricks to Find Winning Biotech Stocks ↗

August 24, 2023

You'll need to dig into company details, but the effort is worthwhile.

Via The Motley Fool

Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M ↗

August 22, 2023

Via Benzinga

Topics Earnings

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

August 22, 2023

Helping save and improve patients' lives in novel ways can be a lucrative activity.

Via The Motley Fool

Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead ↗

August 21, 2023

Via Benzinga

Stocks to Watch This Week’s Top 7 Wall Street Upgrades ↗

August 21, 2023

With the market printing some red ink recently, investors may take greater confidence in the top Wall Street upgrades this week.

Via InvestorPlace

Gene Therapy Breakthroughs On The Horizon ↗

August 21, 2023

Vertex Pharmaceuticals and CRISPR Therapeutics, alongside bluebird bio, are penning a new chapter in the story of gene therapy for sickle cell disease.

Via Talk Markets

3 Green Flags for Biotech Stocks in 2023 and Beyond ↗

August 19, 2023

The industry is changing rapidly, and for the better.

Via The Motley Fool

The 3 Most Undervalued Cathie Wood Stocks to Buy Now: August 2023 ↗

August 16, 2023

Even if Cathie Wood stocks in ARK fell from grace, these three portfolio picks remain undervalued and ideal investments.

Via InvestorPlace

Missed Out on CRISPR Therapeutics? My Best Biotech Stock to Buy and Hold ↗

August 14, 2023

CRISPR Therapeutics is an intriguing biotech stock to consider now.

Via The Motley Fool

3 Reasons to Buy CRISPR Therapeutics Stock, and 1 Reason to Sell ↗

August 12, 2023

This company is in a critical period, and it could soon grow significantly.

Via The Motley Fool

Ready to Buy the Dip? CRISPR Therapeutics Stock Is a Smart Buy ↗

August 11, 2023

Its shares tumbled due to factors outside its control, but the biotech still has substantial long-term potential.

Via The Motley Fool

Cathie Wood Buys Roblox, Palantir Dips — Ark Invest Seizes Buying Opportunities Following Earnings Reports ↗

August 09, 2023

Via Benzinga

The 3 Best Biotech Stocks to Buy in August ↗

August 09, 2023

Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news.

Via InvestorPlace

2 Supercharged Growth Stocks That Could Make You Richer ↗

August 09, 2023

These two biotechs are poised for a sustained period of growth.

Via The Motley Fool

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.